Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Deciphera Pharmaceuticals reports robust Q4 performance and eyes market expansion

Deciphera Pharmaceuticals delivered strong financial results and outlined strategic priorities for future growth.
The company's focus on ctDNA analysis, market expansion, and potential label expansions position them well for continued success.
While facing uncertainties in guideline updates and market competition, Deciphera Pharmaceuticals remains optimistic about growth opportunities.

Deciphera Pharmaceuticals excels in Q1 2023, eyes international expansion

Deciphera Pharmaceuticals demonstrates strong financial performance and strategic achievements in Q1 2023, positioning the company for continued growth and market success.
While facing challenges from market dynamics and competition, the company's focus on international expansion, new drug development, and commercialization efforts presents promising opportunities.
By leveraging strengths in reimbursement ratings, clinical significance of key drugs, and pre-commercial activities, Deciphera is poised to capitalize on market opportunities and drive future growth.

Deciphera Pharmaceuticals excels in Q2, eyes international growth and innovation

Deciphera Pharmaceuticals delivered a standout performance in Q2 2023, driven by QINLOCK's robust revenue generation and international expansion.
While facing challenges such as high operating expenses and clinical trial complexities, the company remains focused on patient outcomes and program advancements.
Opportunities lie in continued revenue growth, clinical program progress, and leadership transitions, positioning Deciphera for future success and innovation.

Deciphera Pharmaceuticals excels in Q3 with record sales and innovative pipeline

Deciphera Pharmaceuticals shows strong financial and clinical performance in Q3 2023.
Balancing successful study outcomes with potential regulatory challenges and patient dynamics.
Company poised for significant revenue growth and market expansion with innovative products.
Continued focus on commercial success and pipeline advancement to drive future growth.

Deciphera Pharmaceuticals reports robust Q4 performance and eyes global expansion

Deciphera Pharmaceuticals showcased strong financial performance, clinical advancements, and strategic plans for growth in Q4 2023, positioning the company for continued success.
While facing challenges in market differentiation and operational execution, the company has opportunities for market expansion, record sales, and clinical development milestones in 2024.
Overall, Deciphera Pharmaceuticals' focus on QINLOCK sales, vimseltinib development, and international expansion underscores a comprehensive growth strategy and potential for market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that the Journal of Clinical Oncology has published results from its INTRIGUE Phase 3 study of QINLOCK® (ripretinib) in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib. Although QINLOCK did not offer a st

Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Jennifer Larson - Senior Vice President, Finance and Investor Relations Steven Hoerter - President and Chief Executive Officer Matthew Sherman - Executive Vice President and Chief Medical Officer Daniel Martin - Senior Vice President and Chief Commercial Officer Margarida Duarte - Senior Vice President and Head of International Tucker Kelly - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Daniel Wolle - JPMorgan Allison Bratzel - Piper Sandler Bradley Canino - Stifel Reni Benjamin - JMP Securities Operator Good day and thank you for standing by. Welcome to the Deciphera Pharmaceuticals' Q2 2022 Conference Call.

Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q2 2022 Results - Earnings Call Transcript

Deciphera (DCPH) reports a narrower-than-expected loss in the second quarter of 2022 while revenues beat estimates. Shares rise.

Deciphera (DCPH) Loss Narrows in Q2, Qinlock Drive Revenues

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the second quarter ended June 30, 2022, and provided a corporate update. “We delivered strong commercial performance in the second quarter with QINLOCK®, and we advanced our portfolio of product candidates with best-in-class pote

Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022. In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 8:00 AM ET on Thursday, August 4, 2022, to

Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 4, 2022

The consensus price target hints at a 26.9% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Deciphera Pharmaceuticals, Inc. (DCPH) Have the Potential to Rally 27% as Wall Street Analysts Expect?

Deciphera Pharmaceuticals, Inc. (DCPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Deciphera Pharmaceuticals, Inc. (DCPH) Report Negative Q2 Earnings? What You Should Know

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Evolus, Inc. (EOLS) have performed compared to their sector so far this year.

Is Deciphera Pharmaceuticals (DCPH) Outperforming Other Medical Stocks This Year?

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

Has Deciphera Pharmaceuticals (DCPH) Outpaced Other Medical Stocks This Year?

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced the appointment of Kelley Dealhoy as Senior Vice President and Chief Business Officer. Ms. Dealhoy brings 20 years of life science leadership experience to the role, and her responsibilities will include developing and leading the Company's business development efforts as well as supporting corporate strategy initiatives. “We are thrilled to welcome Kelley to our executive team as Chief Business Offi

Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

Deciphera (DCPH) Up More Than 30% in Past 3 Months: Here's Why

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?

Deciphera Pharmaceuticals, Inc. (DCPH) Up 4.3% Since Last Earnings Report: Can It Continue?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Margarida Duarte - SVP & Head, International Steven Hoerter - President, CEO & Director Daniel Martin - SVP & Chief Commercial Officer Matthew Sherman - EVP & Chief Medical Officer Thomas Kelly - EVP, CFO & Treasurer Conference Call Participants Daniel Wolle - JPMorgan Chase & Co. Eun Yang - Jefferies Allison Bratzel - Piper Sandler & Co. Paul Jeng - Guggenheim Securities Reni Benjamin - JMP Securities Andrew Berens - SVB Leerink Peter Lawson - Barclays Bank Bradley Canino - Stifel, Nicolaus & Company Maghan Meyers - SVP, Argot Partners Operator Good morning, everyone, and welcome to Deciphera Pharmaceuticals First Quarter 2022 Financial Results Conference Call. Today's call is being recorded.

Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q1 2022 Results - Earnings Call Transcript

Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.

Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 4.76% and 7.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Tops Revenue Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update. “We have made significant progress on our 2022 goals so far this year, demonstrating our commercial success with QINLOCK®, strengthening our balance sheet, and rapidly advancing our potential best-in-class and first-in-class clinical-stage pipeline,” said Steve Hoerter, President and Chief Executive Officer

Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results

The consensus price target hints at a 78.9% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Deciphera Pharmaceuticals, Inc. (DCPH) Climb 79% to Reach the Level Wall Street Analysts Expect?

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2022 financial results on Wednesday, May 4, 2022. In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 8:00 AM ET on Wednesday, May 4, 2022, to discuss the Company's financial results and provide a corporate update. The conference call may be accessed by dialing (877) 270-2148 (domestic) or (412) 902

Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the closing of its underwritten public offering of 7,501,239 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 9,748,761 shares of its common stock at an exercise price of $0.01 per share. The share

Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) has priced an underwritten public offering of 5.25 million shares at $10.00 per share, for gross proceeds of $150 million. The offer price represents a discount of 3.5% from the last close price of $10.36 on Tuesday.

Deciphera Raises $150M Via Equity Offering

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the pricing of an underwritten public offering of 5,251,239 shares of its common stock at a public offering price of $10.00 per share. In addition, in lieu of common stock to certain investors, Deciphera is offering pre-funded warrants to purchase 9,

Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it intends to offer and sell $150,000,000 of shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering. In addition, Deciphera intends to grant the underwriters a 30-day option t

Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since approval. The recent restructuring initiative is saving costs.

4 Reasons to Add Deciphera (DCPH) Stock to Your Portfolio

Johnson & Johnson

Eli Lilly

Vertex Pharmaceuticals

Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.

J&J Sets in Motion Drug/Biotech Q1 Earnings: 3 Stocks to Buy

The mean of analysts' price targets for Deciphera Pharmaceuticals, Inc. (DCPH) points to a 73.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

News for Deciphera Pharmaceuticals Stock (DCPH)